- Home
- PULM vs OVID Comparison
PULM vs OVID Comparison
Compare PULM & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- OVID
- Stock Information
- Founded
- PULM 2003
- OVID 2014
- Country
- PULM United States
- OVID United States
- Employees
- PULM N/A
- OVID N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- PULM Health Care
- OVID Health Care
- Exchange
- PULM Nasdaq
- OVID Nasdaq
- Market Cap
- PULM 20.5M
- OVID 20.6M
- IPO Year
- PULM N/A
- OVID 2017
- Fundamental
- Price
- PULM $4.87
- OVID $1.23
- Analyst Decision
- PULM
- OVID Strong Buy
- Analyst Count
- PULM 0
- OVID 4
- Target Price
- PULM N/A
- OVID $3.13
- AVG Volume (30 Days)
- PULM 11.0K
- OVID 2.0M
- Earning Date
- PULM 08-06-2025
- OVID 08-13-2025
- Dividend Yield
- PULM N/A
- OVID N/A
- EPS Growth
- PULM N/A
- OVID N/A
- EPS
- PULM N/A
- OVID N/A
- Revenue
- PULM $369,000.00
- OVID $6,651,000.00
- Revenue This Year
- PULM N/A
- OVID $708.13
- Revenue Next Year
- PULM $134.88
- OVID N/A
- P/E Ratio
- PULM N/A
- OVID N/A
- Revenue Growth
- PULM N/A
- OVID 1070.95
- 52 Week Low
- PULM $1.78
- OVID $0.24
- 52 Week High
- PULM $10.40
- OVID $1.47
- Technical
- Relative Strength Index (RSI)
- PULM 44.33
- OVID 70.64
- Support Level
- PULM $4.65
- OVID $1.16
- Resistance Level
- PULM $5.00
- OVID $1.30
- Average True Range (ATR)
- PULM 0.16
- OVID 0.11
- MACD
- PULM 0.06
- OVID 0.01
- Stochastic Oscillator
- PULM 76.92
- OVID 78.00
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.